[go: up one dir, main page]

MX343114B - Anticuerpos contra la tweak humana y usos de los mismos. - Google Patents

Anticuerpos contra la tweak humana y usos de los mismos.

Info

Publication number
MX343114B
MX343114B MX2013003592A MX2013003592A MX343114B MX 343114 B MX343114 B MX 343114B MX 2013003592 A MX2013003592 A MX 2013003592A MX 2013003592 A MX2013003592 A MX 2013003592A MX 343114 B MX343114 B MX 343114B
Authority
MX
Mexico
Prior art keywords
diseases
same
antibodies against
against human
human tweak
Prior art date
Application number
MX2013003592A
Other languages
English (en)
Other versions
MX2013003592A (es
Inventor
Knoetgen Hendrik
Baehner Monika
Niewoehner Jens
Original Assignee
F Hoffmann-La Roche Ag *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann-La Roche Ag * filed Critical F Hoffmann-La Roche Ag *
Publication of MX2013003592A publication Critical patent/MX2013003592A/es
Publication of MX343114B publication Critical patent/MX343114B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se refiere a un anticuerpo que se fija sobre la TWEAK y se caracteriza porque como dominio variable de cadena larga contiene una CDR3H elegida entre el grupo formado por las SEC ID NO: 8, 16 ó 24 es útil para el tratamiento del cáncer o de enfermedades autoinmunes, artritis reumatoide, artritis psoriática, enfermedades musculares, por ejemplo, distrofia muscular, esclerosis múltiple, enfermedades renales crónicas, enfermedades óseas, por ejemplo, degeneración ósea en el mieloma múltiple, lupus eritematoso sistémico, nefritis por lupus y las lesiones vasculares.
MX2013003592A 2010-10-05 2011-09-30 Anticuerpos contra la tweak humana y usos de los mismos. MX343114B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10186536 2010-10-05
PCT/EP2011/067070 WO2012045671A1 (en) 2010-10-05 2011-09-30 Antibodies against human tweak and uses thereof

Publications (2)

Publication Number Publication Date
MX2013003592A MX2013003592A (es) 2013-05-31
MX343114B true MX343114B (es) 2016-10-25

Family

ID=43086385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003592A MX343114B (es) 2010-10-05 2011-09-30 Anticuerpos contra la tweak humana y usos de los mismos.

Country Status (22)

Country Link
US (1) US9187564B2 (es)
EP (1) EP2625200A1 (es)
JP (1) JP5941049B2 (es)
KR (1) KR101584416B1 (es)
CN (1) CN103154029B (es)
AR (1) AR083336A1 (es)
AU (1) AU2011311673B2 (es)
BR (1) BR112013007293A2 (es)
CA (1) CA2809632A1 (es)
CL (1) CL2013000901A1 (es)
CR (1) CR20130108A (es)
EA (1) EA201300418A1 (es)
EC (1) ECSP13012542A (es)
HK (1) HK1186195A1 (es)
MA (1) MA34642B1 (es)
MX (1) MX343114B (es)
NZ (1) NZ607588A (es)
PE (1) PE20131411A1 (es)
PH (1) PH12013500506A1 (es)
SG (1) SG188605A1 (es)
TW (1) TWI482630B (es)
WO (1) WO2012045671A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1141027A1 (en) * 1999-01-15 2001-10-10 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
PT1997512E (pt) 2002-04-09 2014-02-20 Biogen Idec Inc Métodos para o tratamento de estados relacionados com tweak
DK2332408T3 (da) 2005-02-17 2013-12-02 Biogen Idec Inc Behandling af neurologiske sygdomme
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA2825081A1 (en) 2011-02-28 2012-09-07 Birgit Bossenmaier Antigen binding proteins
AR085403A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos
KR101674784B1 (ko) * 2012-04-05 2016-11-09 에프. 호프만-라 로슈 아게 인간 tweak 및 인간 il17에 대한 이중특이적 항체 및 이의 용도
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
EP3052128A2 (en) * 2013-10-04 2016-08-10 Biogen MA Inc. Tweak antagonists for treating lupus nephritis and muscle atrophy
CN106573986A (zh) * 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 多特异性抗体
SG11202104463YA (en) 2018-10-31 2021-05-28 Astellas Pharma Inc Anti-human fn14 antibody
CN112180100A (zh) * 2020-09-27 2021-01-05 西安交通大学 Tweak作为鉴别不同类型银屑病的分子标志物的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
JP3537535B2 (ja) 1994-07-14 2004-06-14 株式会社中埜酢店 免疫グロブリンｇ結合糖鎖構造に基づく臨床検査方法
WO1997016064A1 (en) 1995-11-03 1997-05-09 The Mount Sinai Medical Center Methods and compositions for the reduction of xenotransplantation rejection
DK0956351T3 (da) 1996-08-07 2006-02-20 Biogen Idec Inc Tumornekrosefaktorbeslægtet ligand
WO1998033523A1 (en) 1997-01-31 1998-08-06 Biovation Limited Vaccination methods and molecules
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
CN103641885A (zh) 1998-05-06 2014-03-19 基因技术股份有限公司 用离子交换层析纯化蛋白质
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
EP1141027A1 (en) 1999-01-15 2001-10-10 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
PT1997512E (pt) 2002-04-09 2014-02-20 Biogen Idec Inc Métodos para o tratamento de estados relacionados com tweak
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
CA2587018A1 (en) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
EP1853718B1 (en) 2005-02-15 2015-08-05 Duke University Anti-cd19 antibodies and uses in oncology
US20060280738A1 (en) 2005-06-08 2006-12-14 Tedder Thomas F Anti-CD19 antibody therapy for transplantation
US20090068102A1 (en) 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
DK2332408T3 (da) 2005-02-17 2013-12-02 Biogen Idec Inc Behandling af neurologiske sygdomme
WO2006096487A2 (en) 2005-03-07 2006-09-14 Genentech, Inc. Methods and compositions for modulating tweak and fn14 activity
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
EP1888113B1 (en) * 2005-05-27 2014-06-25 Biogen Idec MA Inc. Tweak binding antibodies
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
JP2009526746A (ja) 2005-08-19 2009-07-23 セントカー・インコーポレーテツド タンパク質分解抵抗性の抗体調製物
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2008057634A2 (en) 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
DE102005060813A1 (de) 2005-12-20 2007-06-28 Rheinisch-Westfälische Technische Hochschule Aachen Selektive Markierung der Glykane von Antikörpern mit modifizierten Nukleotidzuckern als Substrate von rekombinanten Galactosyltransferasen
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
CN103154029B (zh) 2015-11-25
MX2013003592A (es) 2013-05-31
TWI482630B (zh) 2015-05-01
SG188605A1 (en) 2013-04-30
AR083336A1 (es) 2013-02-21
US9187564B2 (en) 2015-11-17
CA2809632A1 (en) 2012-04-12
CR20130108A (es) 2013-04-29
KR20130062369A (ko) 2013-06-12
JP2013543383A (ja) 2013-12-05
EA201300418A1 (ru) 2013-09-30
CL2013000901A1 (es) 2013-11-29
AU2011311673A1 (en) 2013-03-14
ECSP13012542A (es) 2013-06-28
TW201219054A (en) 2012-05-16
PE20131411A1 (es) 2013-12-16
US20120121583A1 (en) 2012-05-17
KR101584416B1 (ko) 2016-01-13
WO2012045671A1 (en) 2012-04-12
HK1186195A1 (zh) 2014-03-07
BR112013007293A2 (pt) 2016-06-14
NZ607588A (en) 2014-02-28
EP2625200A1 (en) 2013-08-14
AU2011311673B2 (en) 2015-09-17
CN103154029A (zh) 2013-06-12
JP5941049B2 (ja) 2016-06-29
MA34642B1 (fr) 2013-11-02
PH12013500506A1 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
MX343114B (es) Anticuerpos contra la tweak humana y usos de los mismos.
AR074756A1 (es) Anticuerpos contra la angiopoyetina-2 humana
CY1123549T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
UY34387A (es) Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización.
PE20081478A1 (es) Anticuerpos cd44
CR20140029A (es) Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada
EA201692002A1 (ru) Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
CR20120154A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
GT201400066A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
ECSP15038626A (es) A61k 30/395
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
ECSP16075416A (es) Anticuerpos de il-21
CO6362025A2 (es) Anticuerpos contra la proteína tweak humana y usos de los mismos
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
MX2015017855A (es) Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina y metodos de uso.
NI201200144A (es) Anticuerpos humanizados de il - 25
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
CL2018000726A1 (es) Tratamiento con conjugado syd985 de pacientes con cáncer resistente al tratamiento con t-dm1
BR112013024923A2 (pt) novo anticorpo receptor de il-23 anti-humano
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3
CO6680666A2 (es) Anticuerpos contra la tweak humana y usos de los mismos

Legal Events

Date Code Title Description
FG Grant or registration